Aug 18, 2020 · DR-18 mitigates NK cell dysfunction in MHC class I-deficient tumors, leading to efficient cytolysis of malignant cells.

Phase I clinical trials of recombinant human IL-18 have demonstrated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include activation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo.

Jun 24, 2020 · An engineered version of IL-18 that is resistant to binding by the soluble decoy receptor IL-18BP shows strong anti-tumour activity in mouse models of cancer.

IL-18 bioactivity is chiefly downregulated by a decoy soluble receptor named IL18-binding protein (IL-18BP) that is induced by IFNγ as a negative feedback mechanism. Recent advances indicate promising efficacy of IL-18 at armoring CAR-T cells for the treatment of …

Jan 31, 2025 · Here the authors identify a nuclear short form of IL-18 in cancer cells that can enhance NK cell activation to promote tumor elimination.

Our study has identified that IL-18 may act as a colon cancer suppressor that inhibit the proliferation of colon cancer cells. These findings highlight the potential of IL-18 as a marker for patient prognosis and a therapeutic target in colon cancer.

Nov 1, 2017 · Interleukin (IL)-18, structurally similar to IL-1β, is a member of IL-1 superfamily of cytokines. This cytokine, which is expressed by many human lymphoid and nonlymphoid cells, has an important role in inflammatory processes.

IL-18 could have a pro-tumoral activity in certain types of cancers, such as in pancreatic cancer and multiple myeloma, as discussed in this review, and the source and frequency of IL-18 release may contribute to its effect.

Dec 2, 2016 · Our findings demonstrate that anti-CD19 CAR T cells that constitutively secrete IL-18 significantly increase serum cytokine secretion, enhance CAR T cell persistence, induce long-term B cell aplasia and improve mouse survival, even without any prior preconditioning.

Aug 11, 2011 · The inflammatory cytokine interleukin-18 (IL-18) is known to accumulate in cancer patients, but its pathophysiological role remains unclear. In this study, we show that low levels of circulating IL-18, either exogenous or tumor derived, act to suppress the NK cell arm of tumor immunosurveillance.